Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

Christi Shaw, until Thursday morning the executive in charge of Eli Lilly’s drug division, will become the CEO of Kite Pharma, the unit of biotechnology giant Gilead that is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.